Nevanimibe HCl for the Treatment of Classic CAH
Phase 2
Terminated
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Millendo Therapeutics US, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03669549
- Locations
- 🇧🇷
University of Ribeirão Preto, Medicine Faculty (Faculdade de Medicina) of Ribeirão Preto, Ribeirão Preto, Brazil
🇧🇷Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil
🇨🇿Institute of Endocrinology, Praha 1, Czechia
A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
Phase 2
Terminated
- Conditions
- Cushing Syndrome
- Interventions
- Drug: ATR-101Drug: Placebo
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Millendo Therapeutics US, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03053271
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇬🇧The James Cook University Hospital, Middlesbrough, United Kingdom
MLE4901 vs. Placebo for the Treatment of PCOS
Phase 2
Terminated
- Conditions
- Polycystic Ovary Syndrome (PCOS)
- Interventions
- Drug: PlaceboDrug: MLE4901
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Millendo Therapeutics US, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02865915
- Locations
- 🇺🇸
Palmetto Professional Research, Miami, Florida, United States
🇺🇸Highland Clinical Research, Salt Lake City, Utah, United States
🇺🇸Excell Research, Oceanside, California, United States
© Copyright 2025. All Rights Reserved by MedPath